student centered

Rice University rises with massive $100M gift for innovative new student center

The $100-million donation will fund the planned Moody Center for Student Life and Opportunity. Rendering courtesy of Rice University

Rice University's Owls are soaring of late, with the school just being named the top in Texas and No. 7 in the U.S. Now, the institution known as the "Ivy League of the South" is the recipient of a mammoth gift aimed at a game-changing student center.

The Moody Foundation has granted Rice University a massive $100 million for its planned Moody Center for Student Life and Opportunity, which will replace Rice's current Memorial Center (RMC), and will become a new focal point for the university's 300-acre wooded campus, the school announced.

Notably, this new student center is designed by Sir David Adjaye of Adjaye Associates; the acclaimed architect's other works include the Smithsonian Institution's National Museum of African American History and Culture.

Scheduled to break ground in early 2022 and construction completed in 2023, the brand-new Moody Center for Student Life and Opportunity will maintain some elements of the old RMC, namely the chapel and cloisters. Students and staff can expect demolition of the rest of the existing RMC, per a press release.

Moody's $100 million grant matches the record for the largest gift in the university's history. (Last year, the Robert A. Welch Foundation donated $100 million to the school to establish the innovation-driven Welch Institute.) The Moody Foundation has contributed over $125 million to Rice since 1964, a press release notes.

As part of the Moody $100 million gift, a new Moody Fund for Student Opportunity will support an endowment dedicated to student programs "physically anchored in the new student center and elsewhere in the university," according to the school.

All this supports Rice's recently announced plans for a 20-percent expansion of the undergraduate student body by fall 2025, as CultureMap previously reported.

"We are extremely grateful for this extraordinary philanthropy in support of Rice students," said Rice president David Leebron in a statement. "This gift will enable our students to broaden their engagements and experiences while at Rice in ways that will empower their success throughout their lives. It will also enable us to both connect more deeply with Houston and with the world. This will be the epitome of what an inclusive and outward-looking student center should be."

Elle Moody, a trustee of both the Moody Foundation and Rice, added: "As a Rice University alumna, I know this gift will have a profound and lasting effect on the campus and its students. This investment is supporting much more than just a building. We're investing in every student, so they have access to pursue any endeavor whether it's leadership, artistic, athletic, global or more."

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted